Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
a fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
a fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
-
21
-
22
-
23
-
24
Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula?
Published 2019“…<div><p>Abstract Background: Coronary artery fistula (CAF) is an abnormal connection that links a coronary artery to a cardiac chamber or another major blood vessel. …”
-
25
-
26
-
27
-
28
-
29
-
30
mGluR5 receptor decreased glycinergic currents.
Published 2019“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”
-
31
-
32
Average nearest neighbour analysis before and after filtering of data points.
Published 2022Subjects: -
33
-
34
-
35
Response of small airway tissues infected with EV-D94 and decreasing doses of EV-D68.
Published 2022“…<p>Tissues were infected with 1E7 RNA copies of EV-D94 (equivalent to 2,46E4 TCID50) and 1E7 RNA copies of EV-D68 (3,3E5 TCID50) as well as decreasing doses of the latter. …”
-
36
-
37
-
38
-
39
-
40